On March 2, 2021 Edesa Biotech, Inc. closed a bought deal public offering of 1,562,500 of its common shares, at a price to the public of US$6.40 per share. The gross proceeds were US$10,000,000 before deducting underwriting commissions and discounts and other offering expenses payable by Edesa.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases.
Fasken acted as Canadian counsel to Edesa Biotech, Inc. with a team led by Wojtek Baraniak and including Myroslav Chwaluk, Samuel Li, Kevin Yip and Jordana Keslassy.
Jurisdiction
- Ontario
